These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6197309)

  • 1. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
    Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
    Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
    Waldmeier PC; Baumann PA
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
    Kato T; Dong B; Ishii K; Kinemuchi H
    J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the reversibility of reversible MAO inhibitors.
    Waldmeier PC
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC; Delini-Stula A; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of rat brainstem monoamine oxidase activity by CGP 6085 A.
    Hurst JH; Kulakowski EC
    Life Sci; 1986 Oct; 39(16):1471-7. PubMed ID: 2430159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens.
    Pepper JP; Baumann MH; Ayestas M; Rothman RB
    Brain Res Mol Brain Res; 2001 Mar; 87(2):184-9. PubMed ID: 11245920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
    Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
    Sivam SP
    Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T; Lamensdorf I; Finberg JP
    Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.
    Hazelhoff B; De Vries JB; Dijkstra D; de Jong W; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):50-8. PubMed ID: 2413370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic effect of the irreversible and reversible selective MAO-A inhibitors on rat pineal melatonin biosynthesis.
    Oxenkrug GF; Requintina PJ; McIntyre IM; White K
    J Neural Transm Suppl; 1994; 41():381-4. PubMed ID: 7523585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release.
    Halladay AK; Kirschner E; Hesse K; Fisher H; Wagner GC
    Pharmacol Toxicol; 2001 Nov; 89(5):237-48. PubMed ID: 11881977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
    Finberg JP
    Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.